Abstract
Plexiform neurofibromas (PNFs) are benign tumors of the peripheral nervous system that represent a major source of morbidity in neurofibromatosis type 1 (NF1). A substantial proportion of patients do not respond to current therapies or experience intolerable side effects. Transcriptomic characterization of murine and human PNF at bulk and single-cell resolution identified transforming growth factor–β (TGFβ) signaling as a key upstream regulator, driving aberrant basement membrane (BM) protein production by neoplastic Schwann cells and Fbs. Conditional TGFβ1 overexpression in Nf1-deficient Schwann cells driven by Hoxb7-Cre promoted PNF growth and malignant transformation in vivo. Conversely, pharmacologic inhibition of the type I TGFβ receptor (TGFβRI) reduced PNF tumor burden in Nf1 mutant mice. Proteomic characterization of the extracellular matrix (ECM) showed reduced BM proteins upon TGFβRI inhibition. These findings implicate TGFβ as a potential therapeutic target in PNF and provide insights into the role of TGFβ signaling in orchestrating ECM dynamics in the PNF microenvironment.
| Original language | English |
|---|---|
| Article number | eadu0772 |
| Journal | Science advances |
| Volume | 11 |
| Issue number | 25 |
| Publication status | Published - 20 Jun 2025 |
Bibliographical note
Publisher Copyright: Copyright © 2025 The Authors, some rights reserved.Other keywords
- Animals
- Cell Proliferation
- Disease Models, Animal
- Extracellular Matrix/metabolism
- Humans
- Mice
- Neurofibroma, Plexiform/metabolism
- Neurofibromatosis 1/metabolism
- Neurofibromin 1/genetics
- Receptor, Transforming Growth Factor-beta Type I/metabolism
- Schwann Cells/metabolism
- Signal Transduction
- Transforming Growth Factor beta/metabolism
- Tumor Microenvironment